跳到正文
原文
Nature 健康护理主题·· 5 天前AI 评分35

过程评估:肺癌筛查环境中定位式高强度以人为中心的戒烟支持至关重要

Process evaluation showing the importance of co-located, high-intensity and person-centred smoking cessation support in a lung cancer screening setting

AI 导读

约克郡增强戒烟随机对照试验嵌套过程评估显示,对照组与增强干预组参与者均认同在移动筛查单元提供定位式、持续高强度戒烟支持及即时药物疗法的重要性。筛查单元内干预保真度达97%,筛查后4周降至75%,增强组同期为77%;部分戒烟从业者在两组中均运用了理论驱动的行为改变技术,体现培训存在交叉污染。研究提示应投资专门的肺癌筛查戒烟从业者,把握筛查场景的"可教时刻"以促进戒烟。

正文

Abstract

Evidence regarding optimal integration of smoking cessation is needed to inform implementation of lung cancer screening (LCS) and reduce smoking-related inequalities. The Yorkshire Enhanced Stop Smoking Randomised Controlled Trial tested opt-out, co-located standard best practice (SBP) smoking cessation support (control) versus SBP enhanced with theory-informed, personalised risk information derived from participants’ lung scan results to boost quit motivation (intervention). The intervention was tailored to degree of lung/heart damage, and designed to optimise self-efficacy and response-efficacy for quitting smoking1. Smoking cessation practitioners (SCPs) received bespoke intervention training in delivering theory-informed behaviour change techniques (BCTs). We conducted a nested process evaluation to evaluate the implementation of optimised smoking cessation support compared to SBP. Semi-structured interviews were carried out with 45 trial participants and eight SCPs at 4-, 12- and 52-weeks after screening (participants) or training (SCPs). Interviews were analysed thematically to assess intervention fidelity, exposure, context, contamination and theory. Observations of SCP consultations on the mobile screening unit (n = 84; 4%) and 4-weeks after screening (n = 132; 13%) were analysed to test fidelity, context and contamination. Intervention context was paramount: participants in both trial arms described benefits of co-located and ongoing high-intensity smoking cessation support, with immediate provision of pharmacotherapy. Tailored, non-judgemental care was considered key to initiating and sustaining quitting, particularly for participants at various points along their quit pathway and awaiting a possible lung cancer diagnosis. Fidelity was high (97%) on the screening unit and moderate (75%) 4-weeks after screening, and moderate for the enhanced intervention (77%) 4-weeks after screening. SBP and the intervention was flexibly delivered according to time constraints, participant motivation to quit, anxiety about screening and screening and/or booklet results. There was variation in how participants used and shared their booklets (exposure). Contamination of SCP intervention training was observed, with SCPs delivering theory-informed BCTs across both trial arms e.g. using the LCS context to boost response-efficacy beliefs. Provision of co-located, high intensity and person-centred smoking cessation support was vital, irrespective of trial arm. Investment in specialist LCS smoking cessation practitioners may harness the benefits of LCS as a teachable moment for cessation. Trial registration: www.clinicaltrials.gov/study/NCT03750110 (registered 21/11/2018).

Abbreviations

CI:

Confidence intervals (CI)

COREQ:

Consolidated criteria for reporting qualitative studies

EPPM:

Extended parallel process model

LCS:

Lung cancer screening

PPI:

Patient and public involvement

SBP:

Standard best practice

SCPs:

Smoking cessation practitioners

STROBE:

Strengthening the reporting of observational studies in epidemiology

YESS:

Yorkshire enhanced stop smoking

YLST:

Yorkshire lung screening trial

Acknowledgements

We thank all participants who took part in the study. We acknowledge the contribution of all the YESS study team (Gail Barden, Jannine Brooks, Kate Fraser, Thomas Griffiths, Matthew Hudson, Sue O’Shea, Dianne Presha, Susan Tyrrell, Jill Young, Rebecca Thorley, Harriet Copeland, Alex Ashurst) and the whole YLST teams in delivering these interventions. Thanks to Prof Daniel Farewell for his advice on calculating fidelity score.

Funding

This work was funded by Yorkshire Cancer Research (award references L403 and NOT414). From September 2021, P. Alexandris was supported by the Barts Charity (MRC&U0036). From January 2021, S.L. Quaife was supported by the Barts Charity (MRC&U0036). R.J. Beeken is supported by a Yorkshire Cancer Research Fellowship (L389RB). P.A.J. Crosbie is supported by the Manchester National Institute for Health Research Manchester Biomedical Research Centre (IS-BRC-1215-20007). H. D. Quinn-Scoggins is supported by Health and Care Research Wales as part of the Primary and Emergency Care Research Centre (PRIME) (517195). G. McCutchan is supported by Health and Care Research Wales as part of the Wales Cancer Research Centre (517190). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

Author information

Author notes

  1. Rachael L. Murray and Kate Brain contributed equally to this work.

Authors and Affiliations

  1. Department of Population Medicine, School of Medicine, Cardiff University, 8th Floor, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, UK

    Grace McCutchan, Harriet D. Quinn-Scoggins, Hoang Tong, Pamela Smith & Kate Brain

  2. Wales Cancer Research Centre, School of Medicine, Cardiff University, 8th Floor, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, UK

    Grace McCutchan & Pamela Smith

  3. Division of Population Medicine, PRIME Centre Wales, School of Medicine, Cardiff University, 8th Floor, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, UK

    Harriet D. Quinn-Scoggins

  4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Hoang Tong

  5. Wolfson Institute of Population Health, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK

    Samantha L. Quaife

  6. Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Beckett Street, Leeds, LS9 7TF, UK

    Matthew E. J. Callister & Suzanne Rogerson

  7. Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9JT, UK

    Matthew E. J. Callister, Rebecca J. Beeken & Harriet Copeland

  8. School of Medicine, University of Nottingham, Lifespan and Population Health, Room C109, Clinical Sciences Building, Nottingham City Hospital, Nottingham, NG5 1PB, UK

    Rebecca Thorley, Sarah Lewis & Rachael L. Murray

  9. Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK

    David R. Baldwin

  10. Division of Immunology, Immunity to Infection & Respiratory Medicine, North West Lung Centre, Wythenshawe Hospital, University of Manchester, Manchester, M23 9LT, UK

    Philip A. J. Crosbie

  11. York Trials Unit, Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK

    Qi Wu

Authors

  1. Grace McCutchan
  2. Harriet D. Quinn-Scoggins
  3. Hoang Tong
  4. Pamela Smith
  5. Samantha L. Quaife
  6. Matthew E. J. Callister
  7. Rebecca Thorley
  8. David R. Baldwin
  9. Rebecca J. Beeken
  10. Harriet Copeland
  11. Philip A. J. Crosbie
  12. Sarah Lewis
  13. Suzanne Rogerson
  14. Qi Wu
  15. Rachael L. Murray
  16. Kate Brain

Corresponding author

Correspondence to Grace McCutchan.

Ethics declarations

Competing interests

RT, PC have received payment/honoraria for a webinar with Bayer. DRB has received lecture honoraria with Astra Zeneca, MSD and Roche. RM has received consulting fees from Action on Smoking and Health and Cancer Research UK. RM is a Trustee of Action on Smoking and Health and a member of the Royal College of Physicians Tobacco Advisory Group. All other authors declare no conflicts of interest.

Consent for publication

As part of the consent processes, all participants provided consent for the publication of research findings, including anonymised qualitative quotes.

Ethical approval and consent to participate

Trial participants provided consent for observational data and qualitative interviews as part of the YESS consent procedures. SCPs provided consent for each interview. Ethical approval was granted by the Health Research Authority, East Midlands-Derby Research Ethics Committee (18/EM/2019).

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCutchan, G., Quinn-Scoggins, H.D., Tong, H. et al. Process evaluation showing the importance of co-located, high-intensity and person-centred smoking cessation support in a lung cancer screening setting. Sci Rep (2026). https://doi.org/10.1038/s41598-026-74850-4

Download citation

  • Received: 04 June 2025

  • Accepted: 01 October 2026

  • Published: 15 November 2026

  • DOI: https://doi.org/10.1038/s41598-026-74850-4

Keywords

来源:Nature 健康护理主题 · nature.com